Shown are the effects of low-dose methotrexate (LDM) and placebo on hepatic enzyme levels (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), hematologic measures (mean corpuscular volume, white-cell count, hematocrit level, and hemoglobin level), inflammatory mediators (interleukin-1β, interleukin-6, and high-sensitivity Creactive protein [CRP] levels), and lipid levels (low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, and triglycerides). Data shown are the changes from enrollment to 8 months after randomization. The horizontal line in each box represents the median, the top and bottom of the boxes the interquartile range, and the whiskers 1.5 times the interquartile range.